Abstract

As of October 2012 84 countries had reported at least 1 case of extensively drug resistant tuberculosis (EDR TB). In November 2012, the WHO epidemiological surveillance stated: all new TB cases in the world are 3,7 % of multi-drug resistant tuberculosis (MDR TB); 60,0 % of MDR TB among the new cases of TB are documented in Brazil, China, India, and South Africa.

Highlights

  • Pathology of the gastrointestinal tract (GI) ranks the third place on comorbidity in patients with lung tuberculosis (LTB)

  • It was due to the fact that in some of patients with an unclear diagnosis, who complained of steady loss of appetite, weight loss, discomfort in the epigastric region, and had been visiting a doctor for years, pulmonary tuberculosis was revealed later on [1, 8]

  • Expressed syndrome of the systemic inflammatory response in TBL contributes to the development of a malabsorption syndrome [1, 6, 8]

Read more

Summary

Introduction

Pathology of the gastrointestinal tract (GI) ranks the third place on comorbidity in patients with lung tuberculosis (LTB). A significant incidence of comorbidity is explained by related pathogenetic factors of diseases, but by adverse effects of drugs on the gastrointestinal tract in patients with LTB, the spread among the latter, burdened with social and behavioral factors [2, 5]. One of the reasons for inefficient treatment in LTB is malabsorption of anti-TB drugs taken per os, which causes insufficient drug concentrations in blood and lesions, which favour development of chemoresistant TB [1, 8]. To resolve the problem of effective treatment a parenteral route of administration of anti-TB medicines should be recommended for patients with TB and gastrointestinal comorbidity

Objectives
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.